PTC Therapeutics Inc (PTCT.OQ)
21 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|65||2004||Independent Chairman of the Board|
|57||1998||Chief Executive Officer, Director|
|39||2017||Principal Financial Officer, Principal Accounting Officer, Treasurer|
|38||2017||Chief Operating Officer|
|55||2012||Executive Vice President, Chief Legal Officer and Corporate Secretary|
- BRIEF-PTC Therapeutics Reports Q1 Loss Per Share $0.46
- BRIEF-PTC Therapeutics announces presentation of preliminary data from Part 1,dose finding portion, of ongoing FIREFISH clinical trial
- BRIEF-PTC Therapeutics Prices Public Offering Of Common Stock At $27.04 Per Share
- BRIEF-PTC Therapeutics Announces Proposed Public Offering Of Common Stock
- BRIEF-Ptc Therapeutics Says Firefish Study Of RG7916 In Type 1 Spinal Muscular Atrophy Patients Transitioned Into Pivotal Phase With Dosing First Patient